All In Biotech

Drug Trial Radar · NCT03518320

Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer

A Multicenter Study of TAR-200 in Combination With Nivolumab (OPDIVO) in Subjects With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Scheduled for Radical Cystectomy and Are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy

Last checked: Nov 19, 2026Latest source record: Aug 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

13

Actual

Start

Jan 2, 2019

Primary completion

Dec 11, 2019

Study completion Dec 11, 2019

Sponsor

Lead sponsor
Taris Biomedical LLCIndustry
Sponsor type
Industry
Collaborators
Bristol-Myers Squibb
First posted
May 8, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if TAR-200, an investigational drug delivery system, in combination with nivolumab is safe and tolerable in patients with muscle-invasive bladder cancer (MIBC) who are scheduled for radical cystectomy (RC) during an 84-day dosing cycle induction period comprised of four consecutive 21-day dosing cycles.

Conditions

  • Bladder Cancer TNM Staging Primary Tumor (T) T2
  • Bladder Cancer TNM Staging Primary Tumor (T) T2A
  • Bladder Cancer TNM Staging Primary Tumor (T) T2B
  • Bladder Cancer TNM Staging Primary Tumor (T) T3
  • Bladder Cancer TNM Staging Primary Tumor (T) T3A
  • Bladder Cancer TNM Staging Primary Tumor (T) T3B
  • Bladder Cancer TNM Staging Regional Lymph Node (N) N0
  • Bladder Cancer TNM Staging Regional Lymph Node (N) N1
  • Bladder Cancer TNM Staging Distant Metastasis (M) M0

Interventions

  • Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200Drug

    TAR-200 will be placed in the bladder through an inserter and gradually release gemcitabine for four consecutive 21-day dosing cycles for a total period of approximately 84 days

  • Nivolumab Injection [Opdivo]Drug

    Nivolumab will be given intravenously on specified days for four consecutive 21-day dosing cycles for a total period of approximately 84 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with incidence of treatment emergent adverse events (TEAEs) over 4 consecutive 21-day dosing cycles of TAR-200 in combination with Nivolumab as assessed by CTCAE V4.0.Time frame: Study Day 0 to Study Day 180
  2. Number of participants that do not require treatment discontinuation prior to the scheduled end date due to meeting any of the Subject Stopping Safety criteria or other drug or device related AETime frame: Study Day 0 to Study Day 180

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • DuPage Medical Group

    Hinsdale, Illinois

  • University of Rochester Medical Center

    Rochester, New York

  • Duke University Medical Center

    Durham, North Carolina

  • The University of Oklahoma Stephenson Cancer Center

    Oklahoma City, Oklahoma

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • Vanderbilt University Medical Center

    Nashville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.